semaj83/ctmatch_classification huggingface dataset:
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Postoperative Nausea and Vomiting Nausea and Vomiting, Postoperative Known, specified risk factors for PONV (post operative nausea and vomiting) Undergoing gynecologic or gallbladder surgery  pregnant or breastfeeding post-menopausal
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Pyuria Urinary Tract Infections female patient with non-complicated acute bacterial cystitis  recent (less than one month) urinary tract infection partially treated acute cystitis anatomical or function disease of the lower urinary tract patients received radical pelvic surgery associated bladder stone disease upper urinary tract anomaly or urolithiasis systemic infection with body temperature higher than 38°C known allergic reaction to cranberry or vitamin C pregnant or prepare to be pregnant
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Urinary Tract Infection pre-menopausal woman aged 18-40 years current symptomatic uncomplicated cystitis cystitis is treated with trimethoprim-sulfamethoxazole (TMP-SMX) completion of screening procedures negative screening monolayer Pap smear or hysterectomy history of at least two prior symptomatic UTI's treated within the past 12 months or one pior symptomatic UTI treated in the past six months agree to return for the Randomization Visit (Visit 2) regular menstrual cycles or amenorrheic due to use of a long acting progestin, continuous use of oral contraceptives or hysterectomy willing to insert vaginal capsules without an applicator capable of providing informed consent  complicated cystitis or uncomplicated pyelonephritis cystitis at Visit 1 not treated with TMP-SMX uropathogen resistant to TMP-SMX isolated at Visit 1 and persistent symptoms at Visit 2 or failure to achieve a significant reduction in urine wbc count at Visit 2 vaginal or cervical infection, currently or within the past 21 days, with bacterial vaginosis (treated, symptomatic infection), Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis or Herpes Simplex symptomatic bacterial vaginosis at Visit 1 high risk for sexually transmitted diseases and/or HIV, including: 1. diagnosis of N. gonorrhoeae, C. trachomatis or T. vaginalis on two or more occasions during the previous six months; 2. sexual intercourse with a homosexual/bisexual male in the last 10 years; 3. sexual intercourse with an injection drug user or sex worker in the last 10 years; or 4. shared needles for injected drugs in the last 10 years chronic vaginal, urinary or pelvic symptoms not attributable to UTI recurrent bacterial vaginosis (three or more symptomatic, treated infections in the prior 12 months) pregnancy or within two months of last pregnancy lactation
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 15.0-64.0,  Urinary Tract Infections years or older Living in institutional or non-institutional settings months post spinal cord injury (SCI) prior to entry or have Spina Bifida Loss of bladder function Loss of normal bladder sensation Selected in-patients involved in the Rehab I program Catheter dependent, having either an indwelling urinary catheter or using an external catheter, intermittent catheterization, or vesical urinary diversion (original bladder, whole or in part, serves as the collection receptacle for urine) for bladder management Two or more urinary tract infections (UTI) within the 12 months prior to the study Capable of understanding the purpose of the study and providing informed consent to participate Pursue appropriate follow-up over the course of the study  Any bladder stone(s) Kidney stone(s) greater than 1 cm in size Any obstructing kidney stone regardless of size Nephrostomy tube(s) Supravesical diversion (original bladder is no longer part of the collection receptacle for urine) Congenital genitourinary anomaly that predisposes to UTI Conditions anticipated to require recurrent antibiotic therapy for extraurogenital infection (e.g., recurrent pneumonia, decubitus ulcer) Current immunosuppression Vascular prosthesis Congenital or acquired cardiac disease susceptible to vegetative infections
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Arthritis Septic Patients with acute onset of symptoms of less than or equal to two weeks' duration Patients with infection of only the following joints: ankle, knee, hip, wrist, elbow, or shoulder Patients with proven bacterial infection by positive gram stain or culture of synovial fluid and with white blood cell count in synovial flood consistent with infection (75,000 000 cells/mm3.) Cases with negative synovial fluid cultures if positive blood cultures are present and associated with typical inflammatory synovial fluid changes without other identifiable sources of infection and if antibiotic therapy had been initiated earlier to explain negative synovial fluid cultures Monoarticular arthritis  Gonococcal infections Infected prosthetic joints Adjacent osteomyelitis preceding joint infection Septic arthritis occurring as an incidental event late in the course of otherwise fatal illness Patients that are 17 years old or less Polyarticular arthritis
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Nausea Vomiting Male or female patients 18 years of age or older Patients deemed eligible to undergo autologous bone marrow or peripheral stem cell transplant therapy per usual transplant and  Patients with Non-Hodgkins Lymphoma, Hodgkins Lymphoma or Multiple Myeloma or Amyloidosis Written informed consent Nausea at baseline Chronic use of other antiemetic agent(s) Gastrointestinal obstruction or active peptic ulcer Radiation therapy to pelvis or abdomen within 1 week before or after study day 1 Allogeneic stem cell transplant recipient Aspartate transaminase (AST) > 3x upper limit of normal (ULN) Alanine transaminase (ALT) > 3x ULN Bilirubin > 3x ULN
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Incontinence, Urinary and Urinary Bladder, Overactive Overactive Bladder Female subjects with overactive bladder with symptoms of urgency with urge incontinence and frequency which may be associated with nocturia but without bladder pain Must not be pregnant Must not be of childbearing potential or is willing to use specific barrier methods outlined in the protocol Body weight in the range of = 45 kg and <100 kg  Stage III/IV pelvic organ prolapse with or without cystocele History of interstitial cystitis or bladder related pain Subjects with stress incontinence or mixed incontinence where stress incontinence is the predominant component based on prior history History of pelvic prolapse repair (cystocele or rectocele) or urethral diverticulectomy within six months of screening Subjects with urinary incontinence due to causes other then detrusor over activity (e.g., overflow incontinence) Nocturnal enuresis only Urinary retention, or other evidence of poor detrusor function History of prior anti-incontinence surgery History of radiation cystitis or a history of pelvic irradiation Electrostimulation, biofeedback, or bladder training therapy (behavioral therapy) during the previous month prior to screening, or the intention to initiate such therapies during the study. Pessaries and implants are also excluded
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Fever Nulliparous Maternal age > 18 years of age Estimated gestational age (EGA) > 36 0/7 weeks Active labor (> 4 cm dilated) Epidural anesthesia IUPC in place prior to development of fever Temperature of > 38 degrees Consents to study  Multiparous Maternal age < 18 years of age External tocometer
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Nausea and Vomiting, Postoperative Postoperative Nausea and Vomiting History of PONV (postoperative nausea and vomiting) and/or motion sickness Have not smoked for the last 6 months Having certain abdominal, breast, thyroid or shoulder surgery  Pregnant or breastfeeding Have certain pre-existing medical conditions or take certain medications
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anemia Women older than 18 years 24 hours after delivery (vaginal or caesarean section) Patients are in a clinical obstetric setting Blood loss of more than 1000 mL or Hb decrease ≥ 1,9 g/dL Hb value between 4.8 g/dL and 7.9 g/dL Working knowledge of the national language Written consent for participating this study (informed consent)  Patients with severe preeclampsia/ HELLP syndrome RBC transfusion during or after delivery but before t=0 Patients with malignancy Patients with severe congenital haemolytic disease, like thalassemia or sickle cell disease Patients with compromised immunological status, congenital or acquired by medical treatment or infectious disease (eg. HIV) Severe active infectious disease at the time of proposed Severe cardiac, pulmonary, neurological, metabolic or psychiatric co morbidity (ASA II/III) at the time of proposed Severe physical complaints (tachycardia of more than 100 bpm, dyspnoea, syncope, heart problems) at the time of intended Peripartum death of the newborn, or the newborn being in critical condition on neonatal intensive care
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Psoriasis Psoriasis Vulgaris Psoriasis vulgaris PASI >/= 10 at  Psoriasis arthritis Psoriasis pustulosa Psoriasis palmoplantaris Pregnancy current infectious disease
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Participant has signed and dated the appropriate Informed Consent document Participant must have had symptoms of discomfort or pain in the pelvic region for at least a three (3) month period within the last six (6) months  Participant has continued evidence of facultative Gram negative or enterococcus with a value of ≥ 1000 and ≤ 100,000 CFU/ml in mid-stream urine (VB2), as demonstrated by repeat culture obtained no less than seven (7) days post antibiotic treatment Participant has a calculated creatinine clearance of <60 mL/min Participant has a platelet count <100,000/mm3 Participant is allergic to antiepileptic/antiseizure medications Participant has a known allergy or sensitivity to pregabalin (Lyrica®) Participant is taking thiazolidinedione antidiabetic agents (i.e. rosiglitazone and pioglitazone) Participant has New York Heart Association Class III or IV congestive heart failure Participant has a history of thrombocytopenia, or a bleeding diathesis Participant has a history of prostate, bladder or urethral cancer Participant has a history of alcohol abuse
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 0.5-4.917,  Respiratory Infections Diarrhea Malnutrition Age 6-59 months 2. Either sex 3. Severe malnutrition as defined by the presence of any of the followings Bipedal oedema Weight (measured after correction of dehydration) for height Z score <-3 of the National Center for Health Statistics (NCHS) reference Written informed consent of respective parents/ guardians for participation of the children in the study. 4. Children having diarrhoea (watery or invasive) or cough and cold or both for the last 48 hours  Failure to obtain consent 2. Received a dose of vitamin A within the last three months 3. History of night blindness or eye signs of vitamin A deficiency 4. Measles or history of measles within last 8 weeks [56] 5. Clinical suspicion of TB (evening rise of temperature, loss of appetite, gradual loss of weight, cough, night sweating) after applying modified Kenneth Jones [57], shock other than due to hypovolaemia or hypoglycaemia, congestive cardiac failure, severe sepsis (hypothermia, tachycardia, tachypnea, hypotension) [58], and seizure disorders 6. Trisomy-21 7. Cerebral palsy 8. Any other known chronic disease (e.g. hepatic, renal or congenital disorder) or malignant condition
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Nausea Vomiting Subject is 18 years of age or older Subject has never been treated with cisplatin and is to receive first course of cisplatin-based chemotherapy (>=70 mg/m^2) Subject has a Karnofsky performance score of >=60 Subject has a predicted life expectancy of >=3 months Subject has adequate bone marrow, kidney, and liver function as evidenced by Absolute neutrophil count >=1,500/mm3 and white blood cell count >=3,000/mm3 Platelet count >=100,000/mm3 Aspartate aminotransferase (AST) <=2.5 x upper limit of normal (ULN) range Alanine aminotransferase (ALT) <=2.5 x ULN Bilirubin <=1.5 x ULN, except for subjects with Gilbert's syndrome  Any current treatment or medical history (eg, subject is mentally incapacitated or has a psychiatric disorder) that, in the opinion of the investigator, would confound the results of the study or pose any unwarranted risk in administering study drug to the subject Subject has contraindication to the administration of cisplatin, ondansetron, or dexamethasone including, but not limited to, a history of hypersensitivity to the drugs or their components, severe renal impairment, severe bone marrow suppression, hearing impairment, or systemic fungal infection Subject is scheduled to receive any other chemotherapeutic agent with an emetogenicity level of 3 or above (Hesketh Scale) from Day -2 through Day 6 Subject is scheduled to receive any radiation therapy to the abdomen or pelvis within 5 days prior to and/or during Days 1 through 5 following cisplatin infusion Subject has symptomatic primary or metastatic central nervous system (CNS) disease Subject has ongoing vomiting caused by any etiology or has a history of anticipatory nausea and vomiting